Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Polymixin (B and E) market in this environment.
In terms of revenue, this research report indicated that the global Polymixin (B and E) market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Polymixin (B and E) industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The ????Pfizer aims at producing XX Polymixin (B and E) in 2020, with XX % production to take place in global market, ????Shengxue Dacheng accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Polymixin (B and E) Market by XYZResearch Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Polymixin (B and E) Market?
Pfizer
Shengxue Dacheng
Strides
Apeloa
LIVZON GROUP
LKPC
XELLIA
BIOK
Vetbiochem
VEGA
Huazhong Pharmaceutical
Xellia
Biotika
Cayman Chemical
Ivy Fine Chemicals
United-Rising
Shengdapharm
...
Major Type of Polymixin (B and E) Covered in XYZResearch report:
Intravenous Injection
Intramuscular Injection
Other
Application Segments Covered in XYZResearch Market
Septicemia
Meningitis
Infection
Pertussis
Other
For any other requirements, please feel free to contact us and we will provide you customized report.
Request Sample 
Request Discount 
Inquire Before BuyTable of Contents
Global Polymixin (B and E) Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Intravenous Injection -Product Introduction and Major Manufacturers
1.1.2 Intramuscular Injection -Product Introduction and Major Manufacturers
1.1.3 Other -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Polymixin (B and E) Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis
3.1 China Polymixin (B and E) Market
3.1.1 Top Companies leading Polymixin (B and E) Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China Polymixin (B and E) Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)
3.2 EU Polymixin (B and E) Market
3.2.1 Top Companies leading Polymixin (B and E) Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU Polymixin (B and E) Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)
3.3 USA Polymixin (B and E) Market
3.3.1 Top Companies leading Polymixin (B and E) Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA Polymixin (B and E) Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)
3.4 Japan Polymixin (B and E) Market
3.4.1 Top Companies leading Polymixin (B and E) Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan Polymixin (B and E) Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)
3.5 India Polymixin (B and E) Market
3.5.1 Top Companies leading Polymixin (B and E) Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India Polymixin (B and E) Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)
3.6 Southeast Asia Polymixin (B and E) Market
3.6.1 Top Companies leading Polymixin (B and E) Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia Polymixin (B and E) Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America Polymixin (B and E) Market
3.7.1 Top Companies leading Polymixin (B and E) Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America Polymixin (B and E) Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)
4.1 Polymixin (B and E) Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Polymixin (B and E) Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)
5.1 Global Polymixin (B and E) Sales and Growth Rate (2021-2026)
5.2 Global Polymixin (B and E) Sales Value and Growth Rate (2021-2026)
6 Polymixin (B and E) Competitive Analysis
6.1 Pfizer
6.1.1 Pfizer Company Profiles
6.1.2 Pfizer Product Introduction
6.1.3 Pfizer Polymixin (B and E) Production, Revenue (2015-2020)
6.1.4 SWOT Analysis
6.2 Shengxue Dacheng
6.2.1 Shengxue Dacheng Company Profiles
6.2.2 Shengxue Dacheng Product Introduction
6.2.3 Shengxue Dacheng Polymixin (B and E) Production, Revenue (2015-2020)
6.2.4 SWOT Analysis
6.3 Strides
6.3.1 Strides Company Profiles
6.3.2 Strides Product Introduction
6.3.3 Strides Polymixin (B and E) Production, Revenue (2015-2020)
6.3.4 SWOT Analysis
6.4 Apeloa
6.4.1 Apeloa Company Profiles
6.4.2 Apeloa Product Introduction
6.4.3 Apeloa Polymixin (B and E) Production, Revenue (2015-2020)
6.4.4 SWOT Analysis
6.5 LIVZON GROUP
6.5.1 LIVZON GROUP Company Profiles
6.5.2 LIVZON GROUP Product Introduction
6.5.3 LIVZON GROUP Polymixin (B and E) Production, Revenue (2015-2020)
6.5.4 SWOT Analysis
6.6 LKPC
6.6.1 LKPC Company Profiles
6.6.2 LKPC Product Introduction
6.6.3 LKPC Polymixin (B and E) Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
6.7 XELLIA
6.7.1 XELLIA Company Profiles
6.7.2 XELLIA Product Introduction
6.7.3 XELLIA Polymixin (B and E) Production, Revenue (2015-2020)
6.7.4 SWOT Analysis
6.8 BIOK
6.8.1 BIOK Company Profiles
6.8.2 BIOK Product Introduction
6.8.3 BIOK Polymixin (B and E) Production, Revenue (2015-2020)
6.8.4 SWOT Analysis
6.9 Vetbiochem
6.9.1 Vetbiochem Company Profiles
6.9.2 Vetbiochem Product Introduction
6.9.3 Vetbiochem Polymixin (B and E) Production, Revenue (2015-2020)
6.9.4 SWOT Analysis
6.10 VEGA
6.10.1 VEGA Company Profiles
6.10.2 VEGA Product Introduction
6.10.3 VEGA Polymixin (B and E) Production, Revenue (2015-2020)
6.10.4 SWOT Analysis
6.11 Huazhong Pharmaceutical
6.12 Xellia
6.13 Biotika
6.14 Cayman Chemical
6.15 Ivy Fine Chemicals
6.16 United-Rising
6.17 Shengdapharm
7 Conclusion
| Price : US$ 3500 | Date : Oct 2022 |
| Category : Chemicals and Materials | Pages : 141 |
| Price : US$ 3500 | Date : Oct 2022 |
| Category : Chemicals and Materials | Pages : 163 |
| Price : US$ 3500 | Date : May 2022 |
| Category : Healthcare and Pharmaceuticals | Pages : 110 |
| Price : US$ 3000 | Date : Apr 2022 |
| Category : Medical Devices | Pages : 116 |
| Price : US$ 2150 | Date : Nov 2021 |
| Category : Medical Devices | Pages : 100 |
We are happy to help! Call or write to us
